Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands

Journal of Virology

Volumn 76, Issue 24, 2002, Pages 12900-12907

  Ponnazhagan, Selvarangan ^a   Mahendra, Gandham ^a   Kumar, Sanjay ^a   Thompson, John A ^b   Castillas Jr , Mark ^a  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AVIDIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; LIGAND; PROTEOHEPARAN SULFATE; STREPTAVIDIN; VIRUS FUSION PROTEIN;

ADENO ASSOCIATED VIRUS; ARTICLE; BINDING AFFINITY; CELL TYPE; CONTROLLED STUDY; CROSS LINKING; EMBRYO; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VIVO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SEROTYPE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS MORPHOLOGY; VIRUS RECOMBINANT;

BIOTINYLATION; CELL LINE; DEPENDOVIRUS; GENE THERAPY; GENETIC VECTORS; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; LIGANDS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECOMBINATION, GENETIC; STREPTAVIDIN; TRANSDUCTION, GENETIC;

EID: 0036893196     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.24.12900-12907.2002     Document Type: Article

References (39)

1. Bartlett, J. S., J. Kleinschmidt, R. C. Boucher, and R. J. Samulski. 1999. Targeted adeno-associated virus vector transduction of non-permissive cells mediated by a bispecific F(ab′gamma) 2 antibody. Nat. Biotechnol. 17:181-186.
2. Bartlett, J. S., R. Wilcher, and R. J. Samulski. 2000. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J. Virol. 74:2777-2785.
3. Carter, P. J., and R. J. Samulski. 2000. Adeno-associated viral vectors as gene delivery vehicles. Int. J. Mol. Med. 6:17-27.
4. Cristiano, R. J., and J. A. Roth. 1995. Molecular conjugates: A targeted gene delivery vector for molecular medicine. J. Mol. Med. 73:479-486.
5. Dmitriev, I., E. Kashentseva, B. E. Rogers, V. Krasnykh, and D. T. Curiel. 2000. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J. Virol. 74:6875-6884.
6. Ferrari, F. K., T. Samulski, T. Shenk, and R. J. Samulski. 1996. Secondstrand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 70:3227-3234.
7. Fisher, K. J., G. P. Gao, M. D. Weitzman, R. DeMatteo, J. F. Burda, and J. M. Wilson. 1996. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J. Virol. 70:520-532.
8. Fisher-Adams, G., K. K. JR. Wong, G. Podsakoff, S. J. Forman, and S. Chatterjee. 1996. Integration of adeno-associated virus vectors in CD34+ human hematopoietic progenitor cells after transduction. Blood 88:492-504.
9. Girod, A., M. Ried, C. Wobus, H. Lahm, K. Leike, J. Kleinschmidt, G. Deleage, and M. Hallek. 1999. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat. Med. 5:1052-1056.
10. Hansen, J., K. Qing, H. J. Kwon, C. Mah, and A. Srivastava. 2000. Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J. Virol. 74:992-996.
11. Kipriyanov, S. M., M. Little, H. Kropshofer, F. Breitling, S. Gotter, and S. Dubel. 1996. Affinity enhancement of a recombinant antibody: Formation of complexes with multiple valency by a single-chain Fv fragment-core streptavidin fusion. Protein Eng. 9:203-211.
12. Kube, D., S. Ponnazhagan, and A. Srivastava. 1997. Encapsidation of the adeno-associated virus 2 Rep proteins in progeny virions: Rep-mediated growth inhibition of primary bone marrow stromal cells. J. Virol. 71:7361-7371.
13. Li, X. B., G. S. Liao, Y. Y. Shu, and S.X. Tang. 2000. Brain delivery of biotinylated NGF bounded to an avidin-transferrin conjugate. J. Nat. Toxins 9:73-83.
14. Mah, C., K. Qing, B. Khuntirat, S. Ponnazhagan, X. S. Wang, D. M. Kube, M. C. Yoder, and A. Srivastava. 1998. Adeno-associated virus type 2-mediated gene transfer: Role of epidermal growth factor receptor protein tyrosine kinase in transgene expression. J. Virol. 72:9835-9843.
15. Mizukami, H., N. S. Young, and K. E. Brown. 1996. Adeno-associated virus type 2 binds to a 150-kilodalton cell membrane glycoprotein. Virology 217:124-130.
16. Muzyczka, N. 1992. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol. 158:97-129.
17. Nakaki, M., H. Takikawa, and M. Yamanaka. 1997. Targeting immunotherapy using the avidin-biotin system for a human colon adenocarcinoma in vitro. J. Int. Med. Res. 25:14-23.
18. Paganelli, G., P. Magnani, and F. Fazio. 1993. Pretargeting of carcinomas with the avidin-biotin system. Int. J. Biol. Markers 8:155-159.
19. Ponnazhagan, S., X. S. Wang, M. J. Woody, F. Luo, L. Y. Kang, M. L. Nallari, N. C. Munshi, S. Z. Zhou, and A. Srivastava. 1996. Differential expression in human cells from the p6 promoter of human parvovirus B19 following plasmid transfection and recombinant adeno-associated virus 2 (AAV) infection: Human megakaryocytic leukaemia cells are non-permissive for AAV infection. J. Gen. Virol. 77:1111-1122.
20. + hematopoietic progenitor cells: Donor variation and correlation of expression with cellular differentiation. J. Virol. 71:8262-8267.
21. Ponnazhagan, S., K. A. Weigel, S. P. Raikwar, P. Mukherjee, M. C. Yoder, and A. Srivastava. 1998. Novel recombinant parvovirus B19-based vectors: Erythroid cell-specific delivery and expression of transduced genes. J. Virol. 72:5224-5230.
22. Ponnazhagan, S., D. T. Curiel, D. R. Shaw, R. D. Alvarez, and G. P. Siegal. 2000. Adeno-associated virus for cancer gene therapy. Cancer Res. 61:6313-6321.
23. Ponnazhagan, S., G. Mahendra, D. T. Curiel, and D. R. Shaw. 2001. Adeno-associated virus-mediated transduction of human monocyte-derived dendritic cells: Implications for ex vivo immunotherapy. J. Virol. 75:9493-9501.
24. Qing, K. Y., X. S. Wang, D. M. Kube, S. Ponnazhagan, A. Bajpai, and A. Srivastava. 1997. Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression. Proc. Natl. Acad. Sci. USA 94:10879.
25. Qing, K. Y., C. Mah, J. Hansen, S. Z. Zhou, V. J. Dwarki, and A. Srivastava. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat. Med. 5:71-77.
26. Rabinowitz, J. E., W. Xiao, and R. J. Samulski. 1999. Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology 265:274-285.
27. Reilly, R. M. 1991. Radioimmunotherapy of malignancies. Clin. Pharmacol. 10:359-375.
28. Saga, T., J. N. Weinstein, J. M. Jeong, T. Heya, J. T. Lee, N. Le, C. H. Paik, C. Sung, and R. D. Neumann. 1994. Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabeled streptavidin. Cancer Res. 54:2160-2165.
29. Sakahara, H., and T. Saga. 1999. Avidin-biotin system for delivery of diagnostic agents. Adv. Drug Deliv. Rev. 37:89-101.
30. Sanlioglu, S., P. K. Benson, J. Yang, E. M. Atkinson, T. Reynolds, and J. F. Engelhardt. 2000. Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation. J. Virol. 74:9184-9196.
31. Shi, N., R. J. Boado, and W. M. Pardridge. 2000. Antisense imaging of gene expression in the brain in vivo. Proc. Natl. Acad. Sci. USA 97:14709-14714.
32. Smith, J. S., J. R. Keller, N., C. Lohrey, C. S. McCauslin, M. Ortiz, K. Cowan, and S. E. Spence. 1999. Redirected infection of directly biotinylated recombinant adenovirus vectors through cell surface receptors and antigens. Proc. Natl. Acad. Sci. USA 96:8855-8860.
33. Snyder, R. O. 1999. Adeno-associated virus-mediated gene delivery. J. Gene Med. 1:166-175.
34. Tal, J. 2000. Adeno-associated virus-based vectors in gene therapy. J. Biomed. Sci. 7:279-291.
35. Wilbur, D. S., P. M. Pathare, D. K. Hamlin, P. S. Stayton, R. To, L. A. Klumb, K. R. Buhler, and R. L. Vessella. 1999. Development of new biotin/streptavidin reagents for pretargeting. Biomol. Eng. 16:113-118.
36. Wilchek, M., and E. A. Bayer. 1999. Foreword and introduction to the book (strept)avidin-biotin systems. Biomol. Eng. 16:1-4.
37. Wu, P., W. Xiao, T. Conlon, J. Hughes, M. Agbandje-McKenna, T. Ferkol, T. Flotte, and N. Muzyczka. 2000. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74:8635-8647.
38. Yang, Q., M. Mamounas, G. Yu, S. Kennedy, B. Leaker, J. Merson, F. Wong-Staal, M. Yu, and J. R. Barber. 1998. Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy. Hum. Gene Ther. 9:1929-1937.
39. Yao, Z., M. Zhang, H. Sakahara, T. Saga, Y. Arano, and J. Konishi. 1998. Avidin targeting of intraperitoneal tumor xenografts. J. Natl. Cancer Inst. 90:25-29.